PMC:7556165 / 69222-70499
Annnotations
LitCovid-sample-CHEBI
Id | Subject | Object | Predicate | Lexical cue | chebi_id |
---|---|---|---|---|---|
T191 | 234-242 | Chemical | denotes | peptides | http://purl.obolibrary.org/obo/CHEBI_16670 |
T192 | 498-536 | Chemical | denotes | N-(2-aminoethyl)-1aziridine-ethanamine | http://purl.obolibrary.org/obo/CHEBI_145998 |
T193 | 845-852 | Chemical | denotes | protein | http://purl.obolibrary.org/obo/CHEBI_36080 |
LitCovid-sample-PD-NCBITaxon
Id | Subject | Object | Predicate | Lexical cue | ncbi_taxonomy_id |
---|---|---|---|---|---|
T386 | 411-419 | Species | denotes | SARS-CoV | NCBItxid:694009 |
T387 | 411-415 | Species | denotes | SARS | NCBItxid:694009 |
T388 | 633-641 | Species | denotes | SARS-CoV | NCBItxid:694009 |
T389 | 633-637 | Species | denotes | SARS | NCBItxid:694009 |
T390 | 936-940 | Species | denotes | SARS | NCBItxid:694009 |
T391 | 1091-1107 | Species | denotes | SARS coronavirus | NCBItxid:694009 |
T392 | 1091-1095 | Species | denotes | SARS | NCBItxid:694009 |
LitCovid-sample-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T412 | 0-13 | Sentence | denotes | ACE2 Blockers |
T413 | 14-264 | Sentence | denotes | Blockade of ACE2 receptor could be achieved through specific antibodies (Li et al., 2003), rationally designed small molecules (Dales et al., 2002; Huentelman et al., 2004; Gross et al., 2020; Pillaiyar et al., 2020) or peptides (Huang et al., 2003). |
T414 | 265-453 | Sentence | denotes | Although their efficacy needs to be confirmed, some of these agents are currently available on the market and have been show to effectively block SARS-CoV invasion (Li S.-R. et al., 2020). |
T415 | 454-781 | Sentence | denotes | For instance, the small synthetic inhibitor N-(2-aminoethyl)-1aziridine-ethanamine (NAAE) binds ACE2 active site in its closed conformation; this contact triggers the shifting of SARS-CoV S binding residues preventing the molecular interaction with targeted enzyme and the subsequent cell-cell fusion (Huentelman et al., 2004). |
T416 | 782-980 | Sentence | denotes | Therefore, although ACE2 catalytic site is distinct from the S-protein-binding domain, NAAE exerts dual inhibitory effects on ACE2 catalytic activity and SARS binding (Adedeji and Sarafianos, 2014). |
T417 | 981-1277 | Sentence | denotes | However, since a protecting role for ACE2 receptor against virus-induced acute lung injury in infections with SARS coronavirus has not been excluded (Imai et al., 2005; Kuba et al., 2005; Li S.-R. et al., 2020), the choice of ACE2 inhibition as therapeutic approach should be carefully evaluated. |
LitCovid-sample-PD-UBERON
Id | Subject | Object | Predicate | Lexical cue | uberon_id |
---|---|---|---|---|---|
T149 | 1060-1064 | Body_part | denotes | lung | http://purl.obolibrary.org/obo/UBERON_0002048 |
LitCovid-sample-Pubtator
Id | Subject | Object | Predicate | Lexical cue | pubann:denotes |
---|---|---|---|---|---|
1891 | 0-4 | Gene | denotes | ACE2 | Gene:59272 |
1907 | 26-30 | Gene | denotes | ACE2 | Gene:59272 |
1908 | 550-554 | Gene | denotes | ACE2 | Gene:59272 |
1909 | 802-806 | Gene | denotes | ACE2 | Gene:59272 |
1910 | 908-912 | Gene | denotes | ACE2 | Gene:59272 |
1911 | 1018-1022 | Gene | denotes | ACE2 | Gene:59272 |
1912 | 1207-1211 | Gene | denotes | ACE2 | Gene:59272 |
1913 | 411-419 | Species | denotes | SARS-CoV | Tax:694009 |
1914 | 633-641 | Species | denotes | SARS-CoV | Tax:694009 |
1915 | 1091-1107 | Species | denotes | SARS coronavirus | Tax:694009 |
1916 | 843-852 | Gene | denotes | S-protein | Gene:43740568 |
1917 | 498-536 | Chemical | denotes | N-(2-aminoethyl)-1aziridine-ethanamine | |
1918 | 538-542 | Chemical | denotes | NAAE | |
1919 | 869-873 | Chemical | denotes | NAAE | |
1920 | 1054-1071 | Disease | denotes | acute lung injury | MESH:D055371 |
1921 | 1075-1085 | Disease | denotes | infections | MESH:D007239 |
LitCovid-sample-UniProt
Id | Subject | Object | Predicate | Lexical cue | uniprot_id |
---|---|---|---|---|---|
T6161 | 0-4 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6162 | 26-30 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6163 | 550-554 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6164 | 802-806 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6165 | 843-852 | Protein | denotes | S-protein | https://www.uniprot.org/uniprot/Q9D080|https://www.uniprot.org/uniprot/Q9BSH7|https://www.uniprot.org/uniprot/Q91X32|https://www.uniprot.org/uniprot/Q8VII4|https://www.uniprot.org/uniprot/Q5SYG4|https://www.uniprot.org/uniprot/P48819|https://www.uniprot.org/uniprot/P29788|https://www.uniprot.org/uniprot/P22458|https://www.uniprot.org/uniprot/P04004|https://www.uniprot.org/uniprot/P01141|https://www.uniprot.org/uniprot/B2R7G0 |
T6176 | 908-912 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6177 | 1018-1022 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
T6178 | 1207-1211 | Protein | denotes | ACE2 | https://www.uniprot.org/uniprot/Q9UFZ6 |
LitCovid-sample-PD-IDO
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T279 | 562-566 | http://purl.obolibrary.org/obo/BFO_0000029 | denotes | site |
T280 | 738-742 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
T281 | 743-747 | http://purl.obolibrary.org/obo/CL_0000000 | denotes | cell |
T282 | 817-821 | http://purl.obolibrary.org/obo/BFO_0000029 | denotes | site |
T283 | 1040-1045 | http://purl.obolibrary.org/obo/NCBITaxon_10239 | denotes | virus |
T284 | 1075-1085 | http://purl.obolibrary.org/obo/IDO_0000586 | denotes | infections |
LitCovid-sample-PD-FMA
Id | Subject | Object | Predicate | Lexical cue | fma_id |
---|---|---|---|---|---|
T452 | 738-742 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T453 | 743-747 | Body_part | denotes | cell | http://purl.org/sig/ont/fma/fma68646 |
T454 | 845-852 | Body_part | denotes | protein | http://purl.org/sig/ont/fma/fma67257 |
T455 | 1060-1064 | Body_part | denotes | lung | http://purl.org/sig/ont/fma/fma7195 |
LitCovid-sample-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T407 | 411-419 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T408 | 411-415 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T409 | 633-641 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T410 | 633-637 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T411 | 936-940 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T412 | 1054-1071 | Disease | denotes | acute lung injury | http://purl.obolibrary.org/obo/MONDO_0006502|http://purl.obolibrary.org/obo/MONDO_0015796 |
T414 | 1075-1085 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
T415 | 1091-1095 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
LitCovid-sample-PD-MAT
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T135 | 1060-1064 | http://purl.obolibrary.org/obo/MAT_0000135 | denotes | lung |
LitCovid-sample-PD-GO-BP-0
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T147 | 738-754 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell-cell fusion |
T148 | 738-754 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell-cell fusion |
T149 | 743-754 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
T150 | 913-931 | http://purl.obolibrary.org/obo/GO_0003824 | denotes | catalytic activity |
LitCovid-sample-GO-BP
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T152 | 738-754 | http://purl.obolibrary.org/obo/GO_0140253 | denotes | cell-cell fusion |
T153 | 738-754 | http://purl.obolibrary.org/obo/GO_0045026 | denotes | cell-cell fusion |
T154 | 743-754 | http://purl.obolibrary.org/obo/GO_0000768 | denotes | cell fusion |
T155 | 743-754 | http://purl.obolibrary.org/obo/GO_0000747 | denotes | cell fusion |
LitCovid-PD-HP
Id | Subject | Object | Predicate | Lexical cue | hp_id |
---|---|---|---|---|---|
T77 | 1054-1071 | Phenotype | denotes | acute lung injury | http://www.orpha.net/ORDO/Orphanet_178320 |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
1891 | 0-4 | Gene | denotes | ACE2 | Gene:59272 |
1907 | 26-30 | Gene | denotes | ACE2 | Gene:59272 |
1908 | 550-554 | Gene | denotes | ACE2 | Gene:59272 |
1909 | 802-806 | Gene | denotes | ACE2 | Gene:59272 |
1910 | 908-912 | Gene | denotes | ACE2 | Gene:59272 |
1911 | 1018-1022 | Gene | denotes | ACE2 | Gene:59272 |
1912 | 1207-1211 | Gene | denotes | ACE2 | Gene:59272 |
1913 | 411-419 | Species | denotes | SARS-CoV | Tax:694009 |
1914 | 633-641 | Species | denotes | SARS-CoV | Tax:694009 |
1915 | 1091-1107 | Species | denotes | SARS coronavirus | Tax:694009 |
1916 | 843-852 | Gene | denotes | S-protein | Gene:43740568 |
1917 | 498-536 | Chemical | denotes | N-(2-aminoethyl)-1aziridine-ethanamine | |
1918 | 538-542 | Chemical | denotes | NAAE | |
1919 | 869-873 | Chemical | denotes | NAAE | |
1920 | 1054-1071 | Disease | denotes | acute lung injury | MESH:D055371 |
1921 | 1075-1085 | Disease | denotes | infections | MESH:D007239 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T412 | 0-13 | Sentence | denotes | ACE2 Blockers |
T413 | 14-264 | Sentence | denotes | Blockade of ACE2 receptor could be achieved through specific antibodies (Li et al., 2003), rationally designed small molecules (Dales et al., 2002; Huentelman et al., 2004; Gross et al., 2020; Pillaiyar et al., 2020) or peptides (Huang et al., 2003). |
T414 | 265-453 | Sentence | denotes | Although their efficacy needs to be confirmed, some of these agents are currently available on the market and have been show to effectively block SARS-CoV invasion (Li S.-R. et al., 2020). |
T415 | 454-781 | Sentence | denotes | For instance, the small synthetic inhibitor N-(2-aminoethyl)-1aziridine-ethanamine (NAAE) binds ACE2 active site in its closed conformation; this contact triggers the shifting of SARS-CoV S binding residues preventing the molecular interaction with targeted enzyme and the subsequent cell-cell fusion (Huentelman et al., 2004). |
T416 | 782-980 | Sentence | denotes | Therefore, although ACE2 catalytic site is distinct from the S-protein-binding domain, NAAE exerts dual inhibitory effects on ACE2 catalytic activity and SARS binding (Adedeji and Sarafianos, 2014). |
T417 | 981-1277 | Sentence | denotes | However, since a protecting role for ACE2 receptor against virus-induced acute lung injury in infections with SARS coronavirus has not been excluded (Imai et al., 2005; Kuba et al., 2005; Li S.-R. et al., 2020), the choice of ACE2 inhibition as therapeutic approach should be carefully evaluated. |